Dexmedetomidine for the Treatment of Delirium After Heart Surgery

NCT ID: NCT01140529

Last Updated: 2016-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary hypothesis: Dexmedetomidine is equal or superior to haloperidol and placebo in the treatment of psychomotor confusion in patients who are recovering from heart surgery.

Study design:

Multi-centre, prospective, randomised, placebo-controlled double-blind study of dexmedetomidine vs. haloperidol for treatment of psychomotor confusion after cardiac surgery. Data will be analyzed in two steps: The primary comparison is between placebo and dexmedetomidine. If the effect of dexmedetomidine is significant, a secondary comparison between dexmedetomidine and haloperidol will follow.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Delirium Psychomotor Confusion

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dexmedetomidine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Bolus and continuous infusion

Haloperidol

Group Type ACTIVE_COMPARATOR

Haloperidol

Intervention Type DRUG

Bolus doses

Placebo

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Bolus and continuous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Bolus and continuous infusion

Intervention Type DRUG

Haloperidol

Bolus doses

Intervention Type DRUG

Saline

Bolus and continuous infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Precedex Haldol Vehicle

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 65 years
* Clinical need for treatment of psychomotor confusion unresponsive to standard analgesic medication (RASS +2 to +3)
* Heart surgery and extracorporeal circulation (ECC) within 7 days
* Written informed consent obtained before surgery
* Mentally competent at the time of written informed consent

Exclusion Criteria

* Ongoing neuroleptic, propofol and α2 agonist medication
* Intubated patient
* Uncompensated acute circulatory failure at time of randomisation (severe hypotension with mean arterial pressure \< 55 mmHg despite volume, vasopressors and IABP)
* Severe bradycardia without pacemaker backup (heart rate \< 50 beats/min)
* AV-conduction block II-III (without pacemaker backup)
* Severe hepatic impairment (Serum bilirubin \> 101 µmol/l)
* Lithium therapy
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Thorax-Kärlkliniken

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sten Walther

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sten M Walther, MD PhD

Role: PRINCIPAL_INVESTIGATOR

ThoraxKärlkliniken, University Hospital, Linköping, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ThoraxKärlkliniken, Universitetssjukhuset

Linköping, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3005099

Identifier Type: -

Identifier Source: org_study_id